Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2018
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H1 2018
SUMMARY
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Sodium And Chloride Dependent Glycine Transporter 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Sodium%li%and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Schizophrenia, Bipolar Disorder (Manic Depression), Cancer Pain, Chronic Pain, Cognitive Impairment Associated With Schizophrenia (CIAS), Memory Impairment, Mild Cognitive Impairment, Neuropathic Pain, Parkinson's Disease, Pervasive Developmental Disorder (PDD) and Thalassemia.
Furthermore, this report also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Sodium And Chloride Dependent Glycine Transporter 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Sodium%li%and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Schizophrenia, Bipolar Disorder (Manic Depression), Cancer Pain, Chronic Pain, Cognitive Impairment Associated With Schizophrenia (CIAS), Memory Impairment, Mild Cognitive Impairment, Neuropathic Pain, Parkinson's Disease, Pervasive Developmental Disorder (PDD) and Thalassemia.
Furthermore, this report also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)
- The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Overview
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Companies Involved in Therapeutics Development
ConSynance Therapeutics Inc
F. Hoffmann-La Roche Ltd
Pfizer Inc
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Drug Profiles
bitopertin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNS-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGW-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GlyT1 for Schizophrenia and Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0410120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Dormant Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Discontinued Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Product Development Milestones
Featured News & Press Releases
Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
Dec 06, 2010: Phase II Study With First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia
Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Overview
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Companies Involved in Therapeutics Development
ConSynance Therapeutics Inc
F. Hoffmann-La Roche Ltd
Pfizer Inc
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Drug Profiles
bitopertin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNS-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGW-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GlyT1 for Schizophrenia and Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0410120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Dormant Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Discontinued Products
Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Product Development Milestones
Featured News & Press Releases
Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia
Dec 06, 2010: Phase II Study With First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia
Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by ConSynance Therapeutics Inc, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by ConSynance Therapeutics Inc, H1 2018
Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Pipeline by Pfizer Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
ConSynance Therapeutics Inc
F. Hoffmann-La Roche Ltd
Pfizer Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
ConSynance Therapeutics Inc
F. Hoffmann-La Roche Ltd
Pfizer Inc
